2003
DOI: 10.1046/j.1440-1614.2003.01194.x
|View full text |Cite
|
Sign up to set email alerts
|

A Canadian Programme for Early Intervention in Non-Affective Psychotic Disorders

Abstract: Phase-specific treatment approach and case identification strategies to reduce delay in treatment are likely to substantially improve outcome in nonaffective psychotic disorders compared with what has been reported with traditional approaches.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
101
0
3

Year Published

2005
2005
2018
2018

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 132 publications
(104 citation statements)
references
References 41 publications
(45 reference statements)
0
101
0
3
Order By: Relevance
“…23 Criteria for admission to the treatment program include the presence of symptoms that meet syndromal criteria for a DSM-IV psychotic disorder of at least a 1-week duration; having received antipsychotics for a period not greater than 1 month, and not suffering from organic brain disease, including epilepsy or mental retardation.…”
Section: Methodsmentioning
confidence: 99%
“…23 Criteria for admission to the treatment program include the presence of symptoms that meet syndromal criteria for a DSM-IV psychotic disorder of at least a 1-week duration; having received antipsychotics for a period not greater than 1 month, and not suffering from organic brain disease, including epilepsy or mental retardation.…”
Section: Methodsmentioning
confidence: 99%
“…A total of 402 papers were identified by the search strategy, from which we identified 28 non-overlapping first episode studies that met inclusion criteria (see Appendix 1) (Montague et al, 1989;Barnes et al, 2000;Craig et al, 2000;de Haan et al, 2000;Drake et al, 2000;Ho et al, 2000;Larsen et al, 2000;Black et al, 2001;Verdoux et al, 2001;Cullberg et al, 2002;Malla et al, 2003;Addington et al, 2004;Sim et al, 2004;Chen et al, 2005;Harris et al, 2005;Manchanda et al, 2005;Melle et al, 2005;Oosthuizen et al, 2005;Petersen et al, 2005;Wade et al, 2005;Clarke et al, 2006;Ucok et al, 2006;Wunderink et al, 2006;Crespo-Facorro et al, 2007;Malla et al, 2007;Vyas et al, 2007;Gorna et al, 2008;Yamazawa et al, 2008). The selected studies included a total of 3998 participants.…”
Section: Studies and Patientsmentioning
confidence: 99%
“…Table 1 shows the distribution of DUP, gender and age at onset of participants of whom individual patient data were available at baseline. The follow-up data of 2 studies were incomplete and therefore only baseline data were used in our analysis (Montague et al, 1989;Malla et al, 2003;Melle et al, 2004;Manchanda et al, 2005;Malla et al, 2007).…”
Section: Studies and Patientsmentioning
confidence: 99%
“…Comment alors ces nouveaux programmes de premier Ă©pisode ont-ils pu ĂȘtre adoptĂ©s, et ont-ils pu continuer Ă  ĂȘtre soutenus par les cliniciens et les dĂ©cideurs nationaux/ rĂ©gionaux (McGorry, 2002 ;Malla et al, 2003 ;Joseph et Birchwood, 2005) ? En dĂ©pit d'un autre avertissement fait en 2003 par le RĂ©seau des bases factuelles en santĂ©, bras du bureau rĂ©gional Europe de l'Organisation Mondiale de la SantĂ©, qui disait qu'« il est trop tĂŽt pour juger si ces Ă©quipes de premier Ă©pisode devraient reprĂ©senter une haute prioritĂ© » dans le dĂ©veloppement d'un systĂšme Ă©quilibrĂ© de santĂ© mentale (Thornicroft et Tansella, 2003).…”
unclassified
“…Mais ils sont aussi motivĂ©s par d'autres logiques qui originent d'autres acteurs comme par exemple les firmes pharmaceutiques ou la recherche, les dĂ©partements universitaires, les milieux de dĂ©cision, et les usagers et leurs proches qui sont d'importants protagonistes soutenant ce mouvement. Ces protagonistes continuent Ă  s'engager dans le dĂ©veloppement de cliniques de premier Ă©pisode (McGorry, 2002 ;Malla et al, 2003 ;Joseph et Birchwood, 2005) Dans la psychiatrie francophone, ce mouvement a Ă©mergĂ© au dĂ©but des annĂ©es 90. Il a Ă©tĂ© associĂ© Ă  la montĂ©e des neurosciences, de la gĂ©nĂ©tique, de la psychopharmacologie, alors que le mĂȘme mouvement Ă©mergeait plutĂŽt de l'Ă©pidĂ©miologie clinique, de la santĂ© publique et d'un prĂ©jugĂ© favorable Ă  un systĂšme public de santĂ© Ă  l'UniversitĂ© McMaster ou Oxford .…”
unclassified